Search clinical trials for: High Dose Quadrivalent Influenza Vaccine

Total 2816 results

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old

Healthy Volunteers

China
Novartis Vaccines

Completed

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Influenza

Dominican Republic
Novavax

Terminated

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Influenza, Human

United States
MedImmune LLC

Terminated

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Australia, Korea, Republic of, Peru, Canada, Israel
VaxInnate Corporation
Department of Health and Human Services; Accelovance

Unknown

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Influenza

United States
Sinovac Research and Development Co., Ltd.

Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19

Turkey
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Influenza

United States, Germany, Philippines, Czechia, France
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Influenza

Germany, Spain, United States, Korea, Republic of, Romania, Taiwan
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
Novartis
Novartis Vaccines

Completed

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Influenza

Argentina
Shiraz University of Medical Sciences

Completed

The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients

Hemodialysis Patients

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
Pauline Verdijk
World Health Organization

Completed

Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Poliomyelitis

Poland
GlaxoSmithKline

Active, not recruiting

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Sexually Transmitted Diseases

United States, Germany, Philippines, France, Spain, South Africa, United Kingdom, Brazil
Pfizer

Completed

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

Staphylococcal Infections

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

Influenza

Mexico
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Insight Therapeutics, LLC
Brown University; Case Western Reserve University

Unknown

High-Dose Influenza Vaccine in Nursing Homes

Influenza

United States
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to Influenza Vaccination in Children and Adolescents

Immune Response | Influenza, Human

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
ID Biomedical Corporation, Quebec

Completed

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Influenza

United States
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Active, not recruiting

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

COVID-19

Australia, Costa Rica, Honduras, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

Influenza | Orthomyxoviridae Infections

United States
Novartis Pharmaceuticals

Completed

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Relapsing Multiple Sclerosis

United States
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Suspended

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Human Papillomavirus Infection

United States
Medicago
Health Sciences Centre, Winnipeg, Manitoba; Syneos Health; Public Health Agency...

Completed

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

COVID-19

China
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.

Not yet recruiting

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

SARS-CoV-2
Changchun BCHT Biotechnology Co.
He Bei province Center for Disease control and prevention

Recruiting

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Influenza Prevention

China
University of Rochester

Terminated

Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Influenza
Institute of Medical Biology, Chinese Academy of...
Hebei Center for Disease Control and Prevention

Completed

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (IVV)

Influenza

China
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to FluMist vs. Flucelvax

Immune Response | Influenza, Human

United States
St. Louis University
MedImmune LLC

Completed

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Influenza
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Influenza

Poland
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Active, not recruiting

Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Acute Gastroenteritis

China
University Health Network, Toronto

Withdrawn

Early Flu Shots in SOT

Influenza | Solid Organ Transplant

Canada
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

Neoplasms

United States
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France

3

Subscribe